AR026400A1 - Quimioterapia de combinacion - Google Patents
Quimioterapia de combinacionInfo
- Publication number
- AR026400A1 AR026400A1 ARP000105899A ARP000105899A AR026400A1 AR 026400 A1 AR026400 A1 AR 026400A1 AR P000105899 A ARP000105899 A AR P000105899A AR P000105899 A ARP000105899 A AR P000105899A AR 026400 A1 AR026400 A1 AR 026400A1
- Authority
- AR
- Argentina
- Prior art keywords
- agents
- cancer
- paclitaxel
- combination
- carboplatin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se refiere a un método para tratar tumores utilizando combinaciones de agentes oncolíticos conocidos. El uso de los agentes juntos proporcionainesperadamente una eficacia mayor que si se emplean agentes simples solamente. La quimioterapia del cáncer ha avanzado sustancialmente en anos recientes.Muchos tumores se han tratado efectivamente utiliando compuestos que son ya sea productos que ocurren naturalmente o agentes sintéticos. La quimioterapia delcáncer con frecuencia ocasiona el uso de una co mbinacion de agentes, generalmente como un medio para proporcionar efectos terapéuticos mayores y reducir losefectos individuales cuando se usan solos. Se relaciona con una combinacion sinergística de agentes antineoplásicos, y con un método para tra tar tumores quecomprenden la administracion de la combinacion. Más particularmente proporciona una composicion que comprende, como primer componente, la aceildinalina, comsegundo componente el paclitaxel o la carboplatina. También proporciona una com posicion que comprende los tres agentes juntos. Consisten esencialmente en losprincipios activos antes mencionados, o sales adecuadas de los mismos, junto con excipientes comunes, diluyentes y portadores. En otro método se emplea unacantidad antitumo r de acetildinalina y una cantidad efectiva de paclitaxel para tratar cánceres susceptibles, incluyendo NSCLC (cáncer de célula pulmonar nopequena), cáncer de mamas, cáncer de ovarios, cáncer de cabeza y cuello del utero, mielomas, cáncer de prostata y cáncer pancreático. La figura 1 muestra lasinergia de CI-994 y paclitaxel en las células del cáncer de colon el raton. La figura 2 muestra las actividades antitumor de CI-994, paclitaxel ycarboplatina, cada uno por separado, y el tratamiento de c ombinacion con los tres. Los datos que anteceden establecen una ineraccion favorable entre laacetildinalina en combinacion con paclitaxel o carboplatina, y en combinacion con ambas paclitaxel y carboplatina. De esta manera se proporciona un método pa ratratar neoplasmas susceptibles que comprende la administracion de los agentes anteriormente descriptos. La combinacion generalmente incluirá cada principio
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16488999P | 1999-11-10 | 1999-11-10 | |
US22256100P | 2000-08-03 | 2000-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR026400A1 true AR026400A1 (es) | 2003-02-12 |
Family
ID=26860956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000105899A AR026400A1 (es) | 1999-11-10 | 2000-11-09 | Quimioterapia de combinacion |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1229916A2 (es) |
JP (1) | JP2003513912A (es) |
KR (1) | KR20020060226A (es) |
CN (1) | CN1387438A (es) |
AR (1) | AR026400A1 (es) |
AU (1) | AU1583201A (es) |
CA (1) | CA2386876A1 (es) |
GT (1) | GT200000194A (es) |
HU (1) | HUP0203153A3 (es) |
IL (1) | IL149363A0 (es) |
NZ (1) | NZ518668A (es) |
PA (1) | PA8506201A1 (es) |
PE (1) | PE20011028A1 (es) |
PL (1) | PL355170A1 (es) |
SV (1) | SV2001000212A (es) |
UY (1) | UY26431A1 (es) |
WO (1) | WO2001034131A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
US9115090B2 (en) | 2003-12-02 | 2015-08-25 | The Ohio State University Research Foundation | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors |
US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
MX2007000610A (es) * | 2004-07-16 | 2007-03-07 | Pfizer Prod Inc | Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina. |
PL2415382T3 (pl) | 2010-08-06 | 2013-02-28 | Electrolux Home Products Corp Nv | Zmywarka nablatowa |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ219974A (en) * | 1986-04-22 | 1989-08-29 | Goedecke Ag | N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases |
-
2000
- 2000-11-03 EP EP00978360A patent/EP1229916A2/en not_active Withdrawn
- 2000-11-03 KR KR1020027005970A patent/KR20020060226A/ko not_active Application Discontinuation
- 2000-11-03 PL PL00355170A patent/PL355170A1/xx not_active Application Discontinuation
- 2000-11-03 JP JP2001536131A patent/JP2003513912A/ja active Pending
- 2000-11-03 IL IL14936300A patent/IL149363A0/xx unknown
- 2000-11-03 WO PCT/US2000/030377 patent/WO2001034131A2/en not_active Application Discontinuation
- 2000-11-03 HU HU0203153A patent/HUP0203153A3/hu unknown
- 2000-11-03 AU AU15832/01A patent/AU1583201A/en not_active Abandoned
- 2000-11-03 CA CA002386876A patent/CA2386876A1/en not_active Abandoned
- 2000-11-03 CN CN00815470A patent/CN1387438A/zh active Pending
- 2000-11-03 NZ NZ518668A patent/NZ518668A/en unknown
- 2000-11-07 SV SV2000000212A patent/SV2001000212A/es not_active Application Discontinuation
- 2000-11-09 PE PE2000001196A patent/PE20011028A1/es not_active Application Discontinuation
- 2000-11-09 GT GT200000194A patent/GT200000194A/es unknown
- 2000-11-09 UY UY26431A patent/UY26431A1/es not_active Application Discontinuation
- 2000-11-09 PA PA20008506201A patent/PA8506201A1/es unknown
- 2000-11-09 AR ARP000105899A patent/AR026400A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2386876A1 (en) | 2001-05-17 |
CN1387438A (zh) | 2002-12-25 |
AU1583201A (en) | 2001-06-06 |
WO2001034131A2 (en) | 2001-05-17 |
GT200000194A (es) | 2002-05-03 |
IL149363A0 (en) | 2002-11-10 |
HUP0203153A3 (en) | 2005-01-28 |
EP1229916A2 (en) | 2002-08-14 |
WO2001034131A3 (en) | 2002-05-10 |
PE20011028A1 (es) | 2001-10-12 |
HUP0203153A2 (hu) | 2003-01-28 |
SV2001000212A (es) | 2001-10-25 |
JP2003513912A (ja) | 2003-04-15 |
UY26431A1 (es) | 2000-12-29 |
PA8506201A1 (es) | 2002-12-11 |
KR20020060226A (ko) | 2002-07-16 |
NZ518668A (en) | 2004-04-30 |
PL355170A1 (en) | 2004-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR026400A1 (es) | Quimioterapia de combinacion | |
Messaoudi et al. | Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide | |
Treat et al. | Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. | |
AR048502A1 (es) | Sinergia terapeutica de compuestos anti-cancer | |
AR023400A1 (es) | Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores | |
AR054094A1 (es) | Tratamientos de cancer | |
BR0316004A (pt) | Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina | |
BRPI0417260A (pt) | derivados de azepinoindol como agentes farmacêuticos | |
ES2383771T3 (es) | Homoharringtonina sola o combinada con otros agentes para su utilización en el tratamiento de la leucemia mielógena crónica resistente o intolerante a los inhibidores de la proteína cinasa diferentes al STI571 | |
AR040792A1 (es) | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas | |
Brunner | The rationale of combined radiotherapy and chemotherapy–Joint action of castor and pollux | |
ATE344670T1 (de) | Synergistische kombination zur behandlung von kolorektalkarzinom | |
MX2022006853A (es) | Macrociclos para uso en el tratamiento de enfermedades. | |
CN101355969B (zh) | 包含cyc-682和细胞毒性药物的抗增殖性组合 | |
WO2018044369A3 (en) | Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer | |
Buocikova et al. | Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models | |
ES2164899T3 (es) | Uso de alcaloides de la clase lamellarina en metodos de tratamiento. | |
EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
CY1113509T1 (el) | Ενισχυτης της επιδρασης κατα των ογκων, παραγοντας κατα των ογκων και μεθοδος θεραπειας για τον καρκινο | |
MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
Samantas et al. | Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer: a Hellenic Cooperative Oncology Group Study | |
EA200801670A1 (ru) | Комбинированная противораковая терапия с перфузией изолированного органа | |
Stewart et al. | Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer | |
Emambux et al. | Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma | |
Pirker | Two-versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |